Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels
August 19, 2021 07:30 ET
|
Humacyte, Inc.
In addition to the Company’s eight ongoing clinical trials, HAVs have been used in 13 expanded access cases for emergent life- and limb-saving vascular surgeries at seven hospitals across the...
Humacyte Announces Addition of Chief Commercial Officer and Integration of Commercial-Scale Manufacturing into Clinical Trial Programs
August 17, 2021 07:30 ET
|
Humacyte, Inc.
Appoints proven commercial leader B.J. Scheessele as Chief Commercial OfficerIn-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale...
Alpha Healthcare and Humacyte Announce Nominees for Election to Post-Merger Public Company Board of Directors
August 13, 2021 07:30 ET
|
Humacyte, Inc.
Nominees bring depth and diversity of scientific, commercial and financial experience to Board NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp....
Humacyte Announces Publication of In Vivo Data on Biovascular Pancreas Transplantation for the Treatment of Type 1 Diabetes
August 11, 2021 07:30 ET
|
Humacyte, Inc.
Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes Data published in...
Alpha Healthcare Acquisition Corp. Sets August 24, 2021, for Special Shareholder Meeting to Vote on Humacyte Business Combination
August 04, 2021 16:53 ET
|
Humacyte, Inc.
Special shareholder meeting to approve, among other items, the proposed business combination with Humacyte, Inc. to be held August 24, 2021, at 10:00 a.m. EDTShareholders as of the close of business...
Humacyte Presents Potential of Functional Lung Engineering at Janelia R3 – Replace, Repair, Regenerate Planning Workshop
July 22, 2021 07:30 ET
|
Humacyte, Inc.
DURHAM, N.C., July 22, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale,...
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
June 11, 2021 15:03 ET
|
Humacyte, Inc.
Partnership expanded to include vascular trauma repair outside of the United States.Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. DURHAM, N.C., June ...
Humacyte to Participate in Fireside Chat at Cowen 6th Annual FutureHealth Conference
June 10, 2021 07:30 ET
|
Humacyte, Inc.
DURHAM, N.C., June 10, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale,...
Humacyte Presents In Vivo Data on Biovascular Pancreas Transplantation for Type 1 Diabetes Treatment
June 08, 2021 07:30 ET
|
Humacyte, Inc.
Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patientsData presented at...
Humacyte to Provide Investor Update on June 7
June 04, 2021 07:30 ET
|
Humacyte, Inc.
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale,...